This prospectus supplement and the accompanying prospectus dated March 28, 2024 relate to the offer and sale from time totime of 25,544,352 shares of our common stock, par value $0.001 per share. On July 24, 2026, we entered into Amendment No. 8 (the “Sales Agreement Amendment,” and together with the SalesAgreement (as defined below), the “Amended Sales Agreement”) pursuant to which we increased by 25,000,000 the number of sharesof common stock, par value $0.001 per share, that may be offered and sold under our equity sales agreement dated July 26, 2023, withBUCKLER Securities LLC (“BUCKLER”), B. Riley Securities, Inc. (“B. Riley Securities”), Citizens JMP Securities, LLC (“CitizensCapital Markets”), JonesTrading Institutional Services LLC (“Jones”) and Ladenburg Thalmann & Co. Inc. (“Ladenburg Thalmann”)as sales agents, as amended by Amendment No. 1 dated October 25, 2023, pursuant to which StockBlock Securities LLC(“StockBlock”) was added as an agent, as further amended by Amendment No. 2 dated June 20, 2024 (“Amendment No. 2”), pursuantto which BTIG, LLC (“BTIG”) was added as an agent, as further amended by Amendment No. 3 dated August 23, 2024, pursuant towhich the number of shares of our common stock that may be offered and sold under the agreement was increased by 25,000,000, asfurther amended by Amendment No. 4 dated September 20, 2024, pursuant to which Janney Montgomery Scott LLC (“Janney”) wasadded as an agent, as further amended by Amendment No. 5 dated February 13, 2025, pursuant to which the number of shares of ourcommon stock that may be offered and sold under the agreement was increased by 15,000,000, as further amended by Amendment No.6 dated July 25, 2025, pursuant to which the number of shares of our common stock that may be offered and sold under the agreementwas increased by 9,500,000, as further amended by Amendment No. 7 dated January 28, 2026, pursuant to which the number of sharesof our common stock that may be offered and sold under the agreement was increased by 15,000,000 under the Sales Agreement andJanney was removed and Huntington Securities, Inc. (“Huntington Capital Markets”) was added as a sales agent; each of BUCKLER,B. Riley Securities, BTIG, Citizens Capital Markets, Jones, Ladenburg Thalmann, StockBlock and Huntington Capital Markets,individually, an “Agent” and, collectively, the “Agents.” In accordance with the terms of the Amended Sales Agreement, we may, fromtime to time, issue and sell up to 25,544,352 shares of our common stock through or to the Agents, representing the number of sharesthat remained unsold under the Sales Agreement, in addition to the offer of an additional 25,000,000 shares. All references to “Agents”in this prospectus supplement refer initially to the Agents above, individually or collectively, as applicable, and thereafter to the Agentsabove and such other agents as may be designated by us from time to time in the future. All share numbers in this prospectussupplement and the accompanying prospectus reflect our one-for-five reverse stock split of our common stock, effective on September29, 2023. This prospectus supplement amends and restates in its entirety the prospectus supplement dated January 28, 2026, filed inconnection with Amendment No. 7 and the common stock to which this prospectus supplement relates is offered pursuant to the termsof the Amended Sales Agreement. Our common stock and 7.00% Series C Cumulative Redeemable Preferred Stock (“Series C Preferred Stock”) are listed onthe New York Stock Exchange (the “NYSE”) under the symbols “ARR” and “ARR PRC,” respectively. Sales of the common stock, if any, made by the Agents, as our sales agents, as contemplated by this prospectus supplementand the accompanying prospectus, may be made by means of transactions that are deemed to be “at the market offerings” as defined inRule 415 under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, an indeterminate number of shares of ourcommon stock may be sold, if any, but in no event will we issue and sell more than 25,544,352 shares of our common stock pursuantto the Amended Sales Agreement. We will pay each Agent, acting as sales agent, an aggregate commission of up to 2.0% of the grosssales price per share of our common stock sold through such Agent, under the Amended Sales Agreement. In connection with the saleof shares of our common stock on our behalf, the Agents will be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation of the Agents will bedeemed to be underwriting commissions or discounts. The Agents are not required to sell any specific number or dollar amount of our common stock but will use theircommercially reasonable efforts, consistent with their normal sales and trading practice, as our sales agent, and on the terms andsubject to the conditions of the Amended Sales Agreement, to sell the common stock offered on terms agreed by the Agents and us. Wecannot predict the